Henry Schein (HSIC)
Forward P/E is 15.02x against a peer median of 19.61x, a ratio of 0.77x — well below the 0.90 fair-band floor — with trailing P/E 24.84x and PEG 1.45. Latest-quarter revenue grew 6.7% year over year (PRIMARY, EDGAR), close to the group pace. Value-trap check: revenue is growing, not shrinking, and the group median growth is positive, so the discount stands. Delivered demand check: the Health care distributors group's median growth was 7.2% year over year — demand steady, and this company is growing close to that pace.
What would change this label: Move to FAIRLY PRICED if the forward P/E rises above about 17.6x (0.90x the peer median) at unchanged estimates, or if revenue growth falls below 0% year over year for two quarters. Move further from fair value if the forward P/E falls below about 13.5x while revenue growth stays above 6% year over year.
Henry Schein delivers dental and medical supplies to dentists, doctors and vets. Its shares cost much less than similar distributors — about 15 times expected earnings against about 20 times for peers — while its sales grow at close to the same pace. That makes the shares look undervalued.
Both lines start at 100 on 2020-09-01. Over the full window Henry Schein returned +29.30% and the S&P 500 +118.28% (price returns; dividends not reinvested). Worst peak-to-trough fall for Henry Schein: -32.7% (2022-04-13 to 2023-11-02). Source: Nasdaq official daily history.
What the label rests on
Forward P/E is 15.02x against a peer median of 19.61x, a ratio of 0.77x — well below the 0.90 fair-band floor — with trailing P/E 24.84x and PEG 1.45. Latest-quarter revenue grew 6.7% year over year (PRIMARY, EDGAR), close to the group pace. Value-trap check: revenue is growing, not shrinking, and the group median growth is positive, so the discount stands. Delivered demand check: the Health care distributors group's median growth was 7.2% year over year — demand steady, and this company is growing close to that pace. The company’s forward P/E is 15.0× against a peer median of 19.6×. Its own history: UNVERIFIED — no sourced range available. Sector demand read: Delivered demand check: the Health care distributors group's median latest-quarter revenue growth was 7.2% year over year (SEC filings) — demand steady. This company grew 6.7%, close to that pace. Latest-quarter sales growth was +6.7% versus a year earlier (SEC filings).
| Company | Price (Oct 28, 2026) | Forward P/E | Trailing P/E |
|---|---|---|---|
| Henry Schein (HSIC) | $85.21 | 15.0× | 24.8× |
| CAH | — | 19.6× | 34.2× |
| COR | — | 16.9× | 24.3× |
| MCK | — | 20.8× | 25.8× |
| Peer median | 19.6× |
Multiples: stockanalysis.com (SECONDARY, S&P Global data), fetched Oct 28, 2026. Peer set chosen by sector; the median is the middle value of the set. The label and its numbers were recorded in the programme’s label registry on Oct 28, 2026 and will be scored at 6 and 12 months.
Sales, profit and cash
Gross margin = gross profit divided by sales, from SEC filings.
Free cash flow = cash from operations minus spending on plant and equipment, both from the company’s SEC cash-flow statement. Gaps are quarters where that spending line is not separately tagged in the filings — shown as gaps, never estimated.
| Quarter | Sales | Gross margin | Net income | EPS (GAAP, diluted) | Free cash flow |
|---|---|---|---|---|---|
| Q/E Jun 2026 2026-06-27 | $3.5B | 31.8% | $94M | 0.82 | $212M |
| Q/E Mar 2026 2026-03-28 | $3.4B | 31.8% | $107M | 0.92 | $-122M |
| Q/E Dec 2025 2025-12-27 | $3.4B | 30.9% | $101M | — | $338M |
| Q/E Sep 2025 2025-09-27 | $3.3B | 30.7% | $101M | 0.84 | $141M |
| Q/E Jun 2025 2025-06-28 | $3.2B | 31.4% | $86M | 0.70 | $88M |
| Q/E Mar 2025 2025-03-29 | $3.2B | 31.6% | $110M | 0.88 | $6M |
| Q/E Dec 2024 2024-12-28 | $3.2B | 31.1% | $94M | — | $168M |
| Q/E Sep 2024 2024-09-28 | $3.2B | 31.3% | $99M | 0.78 | $117M |
| Q/E Jun 2024 2024-06-29 | $3.1B | 32.5% | $104M | 0.80 | $259M |
| Q/E Mar 2024 2024-03-30 | $3.2B | 31.9% | $93M | 0.72 | $156M |
| Q/E Dec 2023 2023-12-30 | $3.0B | 30.7% | $18M | — | $-71M |
| Q/E Sep 2023 2023-09-30 | $3.2B | 31.5% | $137M | 1.05 | $191M |
The last twelve reported quarters. Full 24-quarter history sits in the data pack behind this page. A dash means the figure is not tagged as a standalone quarter in the company’s SEC facts (the usual case is the fourth quarter, which many companies only report inside the full-year filing) — it is missing, not zero.
Earnings: getting better or worse?
Each box is one quarter’s earnings per share (EPS). Green means EPS was higher than the same quarter a year earlier; red means lower; a dash means the figure is not tagged in the filings.
Basis: GAAP diluted EPS from SEC company facts, compared with the same quarter a year earlier.
Key facts
| Item | Value |
|---|---|
| Company (legal name in filings) | HENRY SCHEIN INC |
| Chief executive | Frederick M. Lowery (source: https://www.businesswire.com/news/home/20260111291084/en/Henry-Schein-Names-Frederick-M.-Lowery-as-Chief-Executive-Officer) |
| Sector | Health Care — Health Care Distributors — distributes dental and medical supplies and equipment to dentists, doctors and vets |
| Share price (Oct 28, 2026) | $85.21 |
| Market value (market cap) | $9.4B — share price times shares outstanding of 111,446,542 (SEC filings; SEC EDGAR dei EntityCommonStockSharesOutstanding (latest)) |
| Sales, last twelve months | $13.6B |
| Net income, last twelve months | $403M |
| Free cash flow, last twelve months | $569M |
| Latest reported quarter | Q/E Jun 2026 (of 24 quarters in the data pack) |
| Six-year price return vs S&P 500 | +29.30% vs +118.28% |
| Worst peak-to-trough fall | -32.7% (2022-04-13 to 2023-11-02) |
What we could not verify
- TTM GAAP diluted EPS could not be summed from company facts because at least one of the last four quarters (typically Q4) has no standalone tagged EPS; trailing P/E is therefore taken from the labelled secondary source in valuation_label.md.
- Own-history P/E range not yet compiled for this company in the Phase 1 batch run; the label rests on peer-median, growth and PEG evidence.
- Guidance record (each quarter scored against the guidance the company gave the quarter before) is not yet compiled for this company — it is a Phase 2 layer. The earnings strip below therefore uses reported EPS versus a year earlier, which is fully sourced from filings.
The IT factor — the most exciting thing the market is overlooking — is not assessed on an X-Ray page. It belongs to the Deep Dive (Phase 2), where it gets the evidence standard it needs. Leadership-era scoring (the six years split by chief executive) is likewise a Phase 2 layer; this page names the current chief executive only, from a sourced profile.
Sources
- SEC EDGAR submissions — Filing index; company legal name.
https://data.sec.gov/submissions/CIK0001000228.json - SEC EDGAR company facts — Quarterly financial spine: revenue, gross profit, net income, GAAP diluted EPS, operating cash flow, PP&E capex, buybacks, dividends, diluted shares.
https://data.sec.gov/api/xbrl/companyfacts/CIK0001000228.json - Nasdaq official daily history — Daily closes for the company; SPY (assetclass=etf) saved as raw/nasdaq_spy_raw.json over identical dates.
https://api.nasdaq.com/api/quote/HSIC/historical?assetclass=stocks - Valuation multiples and peer figures — stockanalysis.com (SECONDARY, S&P Global data), fetched Oct 28, 2026; see valuation_label.md in the data pack.
Conventions: earliest-filed value per period, as first reported; cash-flow years-to-date differenced quarter by quarter; EPS never differenced; free cash flow = operating cash flow minus plant-and-equipment spending. This page is a dated snapshot — updates are new versions, never silent edits.